Market Overview

VIVUS Submits REMS Amendment To FDA For Qsymia Capsules CIV

VIVUS (NASDAQ: VVUS) today announced that it has submitted an amendment to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia™. The proposed REMS modification would allow dispensing through a broader range of certified pharmacies, specifically select retail pharmacies, to increase access while meeting all requirements of the REMS. The REMS modification was made at the mutual request of VIVUS and the FDA.

Within the current REMS program, Qsymia is available through certified mail order pharmacies that are part of the Qsymia Home Delivery Network, including CVS Pharmacy, Express Scripts and Walgreens. The REMS program includes a Medication Guide, healthcare provider training, patient brochure and other education tools. These same tools also will be available as part of the proposed modified REMS program.

"Our REMS has been, and will continue to be, a key element in the Qsymia launch and we look forward to working with the FDA on the modification request," said Dr. Barbara Troupin, Vice President of Scientific Communication & Risk Management at VIVUS.

Qsymia is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in

See full press release

Posted-In: News Guidance Asset Sales Management M&A Global

 

Related Articles (VVUS)

Around the Web, We're Loving...

Get Benzinga's Newsletters